GI Dynamics® Inc. announced positive EndoBarrier data from the University of Freiburg in Germany showing improvements of cardiovascular risk (CV) biomarkers and predicted 4-year risk of major CV events. he study "Duodenal-Jejunal Bypass Liner (DJBL) Improves Cardiovascular Risk Biomarkers and Predicted 4-Year Risk of Major CV Events in Patients with Type 2 Diabetes and Metabolic Syndrome," published by Natascha Roehlen, MD, of the University of Freiburg, demonstrates CV risk decreased significantly during EndoBarrier implantation and sustained improvements within 6 months after explantation. Between 2012 and 2017, 71 patients diagnosed with type 2 diabetes who presented with metabolic syndrome (MS) 1 were implanted with EndoBarrier. Patient implant duration ranged from 9 to 12 months, with 45 patients completing a follow-up period ranging from 3 to 6 months after explantation. Results show a statistically significant improvement in HbA1c, BMI, fasting plasma glucose, HOMA score (insulin resistance), total cholesterol and Lp-PLA2 (cardiovascular biomarker) during the implant period. At 6 months post-explant, HbA1c, BMI, fasting plasma glucose, HOMA score and Lp-PLA2 remained below baseline. Total cholesterol changed in a significant manner during the implant period and was slightly above baseline at 6 months post-explant. Overall CV risk was estimated by the ADVANCE Risk Engine 2 at the time of EndoBarrier implant, explant and 6 months post-explant. The data show overall CV risk decreased significantly following EndoBarrier implantation and remained stable at 6 months post- explant.